Abstract:Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system (CNS) and the primary cause of non-traumatic neurologic disability in the western world. Infiltration of myelin-specific effector T cells into the CNS is thought to cause demyelination and loss of axons resulting in deficient signal conduction and clinical onset of the disease. Although previously thought to be initiated by T helper 1 (Th1) cells, it has become evident that Th17 cells are also involved (Cua 2003). In addition, CD8+ T cells, macrophages, and B cells are also found in inflammatory infiltrates in the CNS of affected individuals. During the initial phases of the disease, once the myelin-specific peripherally activated T cells penetrate the CNS, they are re-activated by antigen presenting cells presenting their target antigen within the CNS and act to cause damage to axonal myelin through the activation of macrophages and the release of myelin toxic substances (Aktas, Waiczies et al. 2007). One of the main obstacles to recovery and to the treatment of MS is the relatively low efficiency of spontaneous remyelination of axons by oligodendrocytes. In the majority of cases during the early phases of the disease a large amount of oligodendrocytes and their precursors are preserved within the characteristic demyelination plaques and retain the ability to remyelinate. Despite this resident population of remyelinating cells it has been shown that over time remyelination becomes incomplete and fails, resulting in the irreversible neurological damage associated with the disease (Franklin 2002). The direct cause of MS remains unknown but it seems most likely to be a mixture of both genetic susceptibility and environmental factors. Genetic factors had been long suspected to affect the chances of an individual developing MS. It has been known for some time that there is a familial link to the disease with a sharp increase in disease probability if a family member has the disease (Dyment, Ebers et al. 2004), with a direct correlation between how closely related the affected individual is and the probability of developing the disease. The importance of genetic factors was underscored by the fact that adopted children have no statistically significant increase in there disease susceptibility compared to the general population, even if any of their adoptive family members have the disease. Other genetic factors such as gender and race have also been shown to have an effect (Sospedra and Martin 2005).

T cells in the pathogenesis of multiple sclerosis and related therapy

Relationship between T Cell Subsets and Pathogenesis of Multiple Sclerosis

T Helper Cells: The Modulators of Inflammation in Multiple Sclerosis

Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target

Crosstalk between dendritic cells and regulatory T cells: Protective effect and therapeutic potential in multiple sclerosis

Role of the Immunogenic and Tolerogenic Subsets of Dendritic Cells in Multiple Sclerosis.

The Immune Pathogenesis of Multiple Sclerosis

Recent Progress in Multiple Sclerosis Treatment Using Immune Cells as Targets

MicroRNAs As T Lymphocyte Regulators in Multiple Sclerosis

Cellular Based Therapies for the Treatment of Multiple Sclerosis

The CD8 T Cell-Epstein-Barr Virus-B Cell Trialogue: A Central Issue in Multiple Sclerosis Pathogenesis

Role of Follicular CD8+ T Cells Labeled with B Cell Helper Immunotypes in Multiple Sclerosis and a Murine Model

Dysregulated MicroRNA Involvement in Multiple Sclerosis by Induction of T Helper 17 Cell Differentiation

B and T Cells Driving Multiple Sclerosis: Identity, Mechanisms and Potential Triggers

Follicular CD8+ T cells promote immunoglobulin production and demyelination in multiple sclerosis and a murine model

Immunopathogenesis of multiple sclerosis: molecular and cellular mechanisms and new immunotherapeutic approaches

miRNAs Participate in MS Pathological Processes and Its Therapeutic Response.

T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy

Immunomodulatory Therapies of Multiple Sclerosis

TLR9 and its signaling pathway in multiple sclerosis

The Plasticity of Immune Cell Response Complicates Dissecting the Underlying Pathology of Multiple Sclerosis